İrfan KARAHAN, Çağar ALP, Aşkın GÜNGÜNEŞ

Tip 2 diyabet tedavisinde sodyum-glukoz ko-transporter 2 inhibitörleri

Sodyum-glukoz ko-transporter 2 (SGLT-2) inhibitörleri, diyabet tedavisinde yeni kullanmaya başlanılan ajanlardır. Temel etki mekanizması proksimal renal tübülden glukoz reabsorbsiyonunu engelleyerek üriner glukoz ekskresyonunu arttırmaktır. Kan basıncı ve vücut ağırlığı üzerine olumlu etkileri gösterilmiştir. Bunun dışında bazı çalışmalarda kardiyovasküler faydaları da olabileceği gösterilmiştir. Başlıca yan etkileri enfeksiyonlar olup diğer yan etkiler ve ilaç yönetimi bu yazıda tartışılmıştır.

Anahtar Kelimeler:

SGLT-2 inhibitörleri, tip 2 diyabet

Sodium-glucose co-transporter-2 inhibitors in Type 2 diabetes treatment

Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are new agents which are used in diabetes treatment. Mechanism of action is inhibiting of glucose reabsorbation and increasing of urinary glucose excretion from renal proximal tubules. These agents could improve blood pressure and weight gain disorders. Many studies showed some of these agents’ benefits on cardiovascular system. Main adverse effects are infections. Drug management and adverse effects were reviewed in this text.

Keywords:

SGLT-2 inhibitors, type 2 diabetes,

PDF

___

1. Singh SK, Gupta A: SGLT2 inhibitors for treatment of type 2 diabetes mellitus: Focus on canagliflozin. Muller Journal of Medical Sciences and Research 2014;5:166.
2. Balfour PC, Rodriguez CJ, Ferdinand KC: Blood pressure and cardiovascular effects of new and emerging antidiabetic agents. Current hypertension reports 2014;16:455.
3. Liakos A, Karagiannis T, Athanasiadou E et al: Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta‐analysis. Diabetes, Obesity and Metabolism 2014, 16:984-93.
4. Clar C, Gill JA, Waugh N: Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ open 2012;2:e001007.
5. Zaccardi F, Webb D, Htike Z, Youssef D, Khunti K, Davies M: Efficacy and safety of sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes mellitus: systematic review and network meta‐analysis. Diabetes, Obesity and Metabolism 2016;18:783-94.
6. Zinman B, Wanner C, Lachin JM et al: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New England Journal of Medicine 2015;373:2117-128.
7. Neal B, Perkovic V, Mahaffey KW et al: Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. New England Journal of Medicine 2017.
8. Wanner C, Inzucchi SE, Lachin JM et al: Empagliflozin and progression of kidney disease in type 2 diabetes. New England Journal of Medicine 2016;375:323-34.
9. Škrtić M, Yang GK, Perkins BA et al: Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration. Diabetologia 2014;57:2599-602.
10. Liu X-Y, Zhang N, Chen R, Zhao J-G, Yu P: Efficacy and safety of sodium–glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2years. Journal of diabetes and its complications 2015;29:1295-303.
11. Inagaki N, Kondo K, Yoshinari T, Kuki H: Efficacy and safety of canagliflozin alone or as add‐on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: A 52‐week open‐label study. Journal of diabetes investigation 2015;6:210-8.
12. Nauck MA: Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug design, development and therapy 2014;8:1335.
13. Inzucchi SE, Zinman B, Wanner C et al: SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diabetes and Vascular Disease Research 2015;12:90-100.
14. Musso G, Gambino R, Cassader M, Pagano G: A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials. Annals of medicine 2012;44:375-93.
15. Moses RG, Colagiuri S, Pollock C: SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes. The Australasian medical journal 2014;7:405. 16. Rosenwasser RF, Sultan S, Sutton D, Choksi R, Epstein BJ: SGLT-2 inhibitors and their potential in the treatment of diabetes. Diabetes, metabolic syndrome and obesity: targets and therapy 2013;6:453.
17. Weir MR, Januszewicz A, Gilbert RE et al: Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus. The Journal of Clinical Hypertension 2014;16:875-82.
18. Berns JS, Glickman JD, Golper TA, Nathan DM, Lam AQ, Mulder JE: Management of hyperglycemia in patients with type 2 diabetes and pre-dialysis chronic kidney disease or end-stage renal disease. In.: UpToDate; 2015.
19. Watts NB, Bilezikian JP, Usiskin K et al: Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. The Journal of Clinical Endocrinology 2016;101:157-66.
20. Alba M, Xie J, Fung A, Desai M: The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus. Current medical research and opinion 2016;32:1375-85.
21. Bilezikian JP, Watts NB, Usiskin K, Polidori D, Fung A, Sullivan D: Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin. The Journal of Clinical Endocrinology 2016;101:44-51.
22. Peters AL, Buschur EO, Buse JB et al: Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium–glucose cotransporter 2 inhibition. Diabetes care 2015, 38:1687-93.
23. Fralick M, Schneeweiss S, Patorno E: Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor. New England Journal of Medicine 2017;376:2300-2.
24. Neal B, Perkovic V, de Zeeuw D et al: Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—a randomized placebo-controlled trial. American heart journal 2013;166:217-23.e211.
25. Neal B, Perkovic V, Matthews DR et al: Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal (CANVAS‐R): A randomized, placebo‐controlled trial. Diabetes, Obesity and Metabolism 2017;19:387-93.